Mantle Cell Lymphoma | Specialty

Dr. Martin on the Potential Role of LOXO-305 in MCL

March 5th 2021

Peter Martin, MD, discusses the potential role of LOXO-305 in mantle cell lymphoma.

Dr. Till on the Potential to Utilize CAR T-Cell Therapy Earlier in MCL

March 4th 2021

Brian Till, MD, discusses the potential to utilize CAR T-cell therapy earlier in the treatment of patients with mantle cell lymphoma.

Dr. Martin on Potential Combination Strategies With BTK Inhibitors in MCL

March 1st 2021

Peter Martin, MD, discusses potential combination regimens with BTK inhibitors in mantle cell lymphoma.

Martin Makes Sense of the Rapidly Evolving MCL Treatment Paradigm

March 1st 2021

As more options emerge in the mantle cell lymphoma paradigm, choosing among the agents available has become all the more challenging.

Dr. Martin on Potential Drug-Drug Interactions With BTK Inhibitors in MCL

February 26th 2021

Peter Martin, MD, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Cirmtuzumab/Ibrutinib Shows Encouraging Clinical Activity, Safety in MCL and CLL

February 26th 2021

Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.

CD19-Targeted CAR T-Cell Therapies Induce Durable Remissions in Several Lymphoma Subtypes

February 26th 2021

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

KTE-X19 Continues to Elicit Durable Responses in Relapsed/Refractory MCL

February 24th 2021

February 24, 2021 - The CAR T-cell product KTE-X19 continues to demonstrate durable clinical benefit in patients with relapsed/refractory mantle cell lymphoma, with an overall response rate of 92%.

Dr. Neelapu on Emerging CAR T-Cell Therapies in Relapsed/Refractory MCL

February 24th 2021

Sattva Neelapu, MD, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma.

Ibrutinib/Venetoclax Demonstrates Encouraging Efficacy in Relapsed/Refractory MCL

February 23rd 2021

Constantine S. Tam, MD, discusses the key findings of the phase 3 SYMPATICO study and where this combination might fit best into a sequence of therapies.